JP2018184470A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018184470A5 JP2018184470A5 JP2018145681A JP2018145681A JP2018184470A5 JP 2018184470 A5 JP2018184470 A5 JP 2018184470A5 JP 2018145681 A JP2018145681 A JP 2018145681A JP 2018145681 A JP2018145681 A JP 2018145681A JP 2018184470 A5 JP2018184470 A5 JP 2018184470A5
- Authority
- JP
- Japan
- Prior art keywords
- empty
- sphingomyelin
- mixture
- cholesterol
- liposomes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002502 liposome Substances 0.000 claims description 53
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 44
- 239000000203 mixture Substances 0.000 claims description 33
- 235000012000 cholesterol Nutrition 0.000 claims description 22
- 150000002632 lipids Chemical class 0.000 claims description 16
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 10
- 208000035143 Bacterial infection Diseases 0.000 claims description 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 7
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 5
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 5
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 5
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 5
- -1 sphingomyelin Chemical compound 0.000 claims description 5
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 4
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 4
- 229940106189 ceramide Drugs 0.000 claims description 4
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 4
- 150000001982 diacylglycerols Chemical class 0.000 claims description 4
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 235000003441 saturated fatty acids Nutrition 0.000 claims description 4
- 150000004671 saturated fatty acids Chemical class 0.000 claims description 4
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 4
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 4
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000031729 Bacteremia Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010057190 Respiratory tract infections Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000001147 anti-toxic effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 238000002651 drug therapy Methods 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 230000035807 sensation Effects 0.000 claims 1
- 206010040882 skin lesion Diseases 0.000 claims 1
- 231100000444 skin lesion Toxicity 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- 229930182558 Sterol Natural products 0.000 description 3
- 150000002313 glycerolipids Chemical class 0.000 description 3
- 150000003408 sphingolipids Chemical class 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 150000008103 phosphatidic acids Chemical class 0.000 description 2
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12171924.9 | 2012-06-14 | ||
| EP12171924 | 2012-06-14 | ||
| EP13153039 | 2013-01-29 | ||
| EP13153039.6 | 2013-01-29 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516609A Division JP6382801B2 (ja) | 2012-06-14 | 2013-06-13 | 細菌感染症の処置のためのテイラーメードされたリポソーム |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018184470A JP2018184470A (ja) | 2018-11-22 |
| JP2018184470A5 true JP2018184470A5 (enExample) | 2019-01-10 |
| JP6656321B2 JP6656321B2 (ja) | 2020-03-04 |
Family
ID=48703423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516609A Active JP6382801B2 (ja) | 2012-06-14 | 2013-06-13 | 細菌感染症の処置のためのテイラーメードされたリポソーム |
| JP2018145681A Active JP6656321B2 (ja) | 2012-06-14 | 2018-08-02 | 細菌感染症の処置のためのテイラーメードされたリポソーム |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015516609A Active JP6382801B2 (ja) | 2012-06-14 | 2013-06-13 | 細菌感染症の処置のためのテイラーメードされたリポソーム |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US10744089B2 (enExample) |
| EP (2) | EP3782606A1 (enExample) |
| JP (2) | JP6382801B2 (enExample) |
| CN (2) | CN104602672B (enExample) |
| AU (2) | AU2013276565B2 (enExample) |
| BR (1) | BR112014031278B1 (enExample) |
| CA (1) | CA2875470C (enExample) |
| CY (1) | CY1123337T1 (enExample) |
| DK (1) | DK2861214T3 (enExample) |
| ES (1) | ES2821502T3 (enExample) |
| HR (1) | HRP20201761T1 (enExample) |
| HU (1) | HUE051761T2 (enExample) |
| LT (1) | LT2861214T (enExample) |
| PL (1) | PL2861214T3 (enExample) |
| RS (1) | RS60951B1 (enExample) |
| RU (1) | RU2672106C2 (enExample) |
| SI (1) | SI2861214T1 (enExample) |
| SM (1) | SMT202000584T1 (enExample) |
| WO (1) | WO2013186286A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104602672B (zh) * | 2012-06-14 | 2018-12-25 | 伯尔尼大学 | 用于治疗细菌感染的定制脂质体 |
| US20170000875A1 (en) | 2013-12-02 | 2017-01-05 | Arytha Biosciences, Llc | Toxoid preparation and uses thereof |
| US10739353B2 (en) * | 2014-12-31 | 2020-08-11 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
| US20200281950A1 (en) * | 2015-12-28 | 2020-09-10 | Mb Biotech Ltd. | Liposomes for treatment of an autoimmune disease |
| WO2017177073A1 (en) * | 2016-04-07 | 2017-10-12 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Francisella lipids as broad anti-inflammatory therapeutics and associated methods of use |
| PT3471732T (pt) | 2016-06-16 | 2020-08-24 | Combioxin Sa | Lipossomas para o tratamento de infeções virais |
| CN110636839B (zh) * | 2017-03-02 | 2023-06-27 | 康柏辛股份有限公司 | 抑制生物膜形成的脂质体 |
| US11344497B1 (en) * | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| EP3781172B1 (en) | 2018-04-17 | 2023-08-30 | Combioxin SA | Treatment of pneumonia |
| EP3781210B1 (en) * | 2018-04-20 | 2024-08-07 | Combioxin SA | Treatment of hypotension with sepsis or septic shock |
| CN111214439B (zh) * | 2018-11-23 | 2023-02-10 | 复旦大学 | 一种具有细菌成孔毒素吸附性能的纳米药物系统及其用途 |
| WO2021150460A1 (en) | 2020-01-20 | 2021-07-29 | Arytha Biosciences Llc | Devices containing cellular membrane and uses thereof |
| WO2022026170A1 (en) * | 2020-07-31 | 2022-02-03 | Signpath Pharma, Inc. | Suppression of cytokine release and cytokine storm |
| CN115054577B (zh) * | 2022-05-17 | 2024-06-21 | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 纳米解毒剂及其在中和mrsa穿孔毒素的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3641247A (en) | 1970-12-14 | 1972-02-08 | Stanley Drug Products Inc | Methods of treating bacterial infections |
| AU6428890A (en) * | 1989-09-12 | 1991-04-18 | Regents Of The University Of California, The | Therapeutic peptides and proteins |
| NL9000207A (enExample) * | 1990-01-29 | 1991-08-16 | Duphar Int Res | |
| AU2583892A (en) | 1991-09-11 | 1993-04-05 | Pitman-Moore, Inc. | Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides |
| US5741516A (en) * | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5543152A (en) * | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| US8110217B2 (en) * | 2001-08-13 | 2012-02-07 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
| US20050118250A1 (en) * | 2001-11-13 | 2005-06-02 | Paul Tardi | Lipid carrier compositions with enhanced blood stability |
| CA2368656A1 (en) * | 2002-01-21 | 2003-07-21 | Vasogen Ireland Limited | Receptor-ligand pairing for anti-inflammatory response |
| KR100746141B1 (ko) | 2002-03-08 | 2007-08-06 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 전시냅스성 단백질 р120 |
| AU2003265241A1 (en) | 2002-05-23 | 2003-12-12 | Activbiotics, Inc. | Methods of treating bacterial infections and diseases associated therewith |
| WO2004047800A2 (en) * | 2002-11-26 | 2004-06-10 | Gilead Sciences, Inc. | Method of drug loading in liposomes by gradient |
| EP1610763A2 (en) * | 2003-03-31 | 2006-01-04 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer |
| CA2821167C (en) | 2004-05-03 | 2016-06-28 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
| JP4990786B2 (ja) * | 2004-11-05 | 2012-08-01 | イネックス ファーマシューティカルズ コーポレイション | 薬物リポソーム製剤を安定化するための組成物および方法 |
| US20090186073A1 (en) | 2005-08-11 | 2009-07-23 | National Institute Of Advanced Industrial Science And Technology | Design of Delivery Vehicle Based On Rolling Model |
| CN1939340A (zh) * | 2005-09-29 | 2007-04-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 脂质体制剂 |
| WO2008039989A2 (en) * | 2006-09-28 | 2008-04-03 | Transave, Inc. | Formulations of dnase and methods of use thereof |
| EP2088865B1 (en) * | 2006-11-06 | 2015-10-21 | Jina Pharmaceuticals Inc. | Guggulphospholipid methods and compositions |
| CN1994279A (zh) * | 2006-12-31 | 2007-07-11 | 西安力邦医药科技有限责任公司 | 注射用盐酸伊立替康脂质体的制备方法 |
| US8906855B2 (en) | 2007-12-22 | 2014-12-09 | Vivacelle Bio, Inc. | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries |
| CN101623262B (zh) * | 2009-08-24 | 2011-02-02 | 海南美大制药有限公司 | 一种五水头孢唑啉钠前体脂质体制剂 |
| CA2803317A1 (en) * | 2010-06-19 | 2011-12-22 | Western University Of Health Sciences | Novel formulation of pegylated-liposome encapsulated glycopeptide antibiotics |
| WO2012021107A2 (en) * | 2010-08-12 | 2012-02-16 | Nanyang Technological University | A liposomal formulation for ocular drug delivery |
| CN102327220B (zh) | 2011-07-14 | 2012-09-26 | 海南灵康制药有限公司 | 一种氯雷他定脂质体固体制剂 |
| CN104602672B (zh) | 2012-06-14 | 2018-12-25 | 伯尔尼大学 | 用于治疗细菌感染的定制脂质体 |
| US10716756B2 (en) | 2016-06-20 | 2020-07-21 | Vivacelle Bio, Inc. | Compositions and methods for reducing reperfusion injury |
| CN110636839B (zh) | 2017-03-02 | 2023-06-27 | 康柏辛股份有限公司 | 抑制生物膜形成的脂质体 |
| EP3781172B1 (en) | 2018-04-17 | 2023-08-30 | Combioxin SA | Treatment of pneumonia |
-
2013
- 2013-06-13 CN CN201380031384.7A patent/CN104602672B/zh active Active
- 2013-06-13 EP EP20189368.2A patent/EP3782606A1/en active Pending
- 2013-06-13 BR BR112014031278-8A patent/BR112014031278B1/pt active IP Right Grant
- 2013-06-13 AU AU2013276565A patent/AU2013276565B2/en active Active
- 2013-06-13 PL PL13732388T patent/PL2861214T3/pl unknown
- 2013-06-13 RU RU2014148284A patent/RU2672106C2/ru active
- 2013-06-13 DK DK13732388.7T patent/DK2861214T3/da active
- 2013-06-13 LT LTEP13732388.7T patent/LT2861214T/lt unknown
- 2013-06-13 CA CA2875470A patent/CA2875470C/en active Active
- 2013-06-13 SI SI201331806T patent/SI2861214T1/sl unknown
- 2013-06-13 ES ES13732388T patent/ES2821502T3/es active Active
- 2013-06-13 RS RS20201252A patent/RS60951B1/sr unknown
- 2013-06-13 WO PCT/EP2013/062207 patent/WO2013186286A1/en not_active Ceased
- 2013-06-13 US US14/404,985 patent/US10744089B2/en active Active
- 2013-06-13 EP EP13732388.7A patent/EP2861214B1/en active Active
- 2013-06-13 JP JP2015516609A patent/JP6382801B2/ja active Active
- 2013-06-13 CN CN201811433069.8A patent/CN109549925B/zh active Active
- 2013-06-13 HU HUE13732388A patent/HUE051761T2/hu unknown
- 2013-06-13 SM SM20200584T patent/SMT202000584T1/it unknown
- 2013-06-13 HR HRP20201761TT patent/HRP20201761T1/hr unknown
-
2018
- 2018-08-02 JP JP2018145681A patent/JP6656321B2/ja active Active
-
2019
- 2019-03-14 AU AU2019201776A patent/AU2019201776B2/en active Active
-
2020
- 2020-07-09 US US16/924,539 patent/US20200345639A1/en not_active Abandoned
- 2020-09-16 CY CY20201100878T patent/CY1123337T1/el unknown
-
2021
- 2021-11-30 US US17/537,862 patent/US20220087934A1/en not_active Abandoned
-
2022
- 2022-09-30 US US17/957,402 patent/US12599558B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519383A5 (enExample) | ||
| JP2015515992A5 (enExample) | ||
| HRP20201761T1 (hr) | Prilagođeni liposomi za tretman bakterijskih infekcija | |
| EP3964200A1 (en) | Compositions and methods for delivery of therapeutic agents | |
| JP2014532665A5 (enExample) | ||
| JP2019023243A5 (enExample) | ||
| AU2013296651B2 (en) | Cochleates made with soy phosphatidylserine | |
| RU2014120216A (ru) | Комбинационные липосомальные композиции для лечения рака | |
| US20220241302A1 (en) | Surfactant Lipids, Compositions Thereof, and Uses Thereof | |
| JP2012516889A (ja) | 微生物因子の増殖及び生存能力を低下させる方法 | |
| JP2006509750A5 (enExample) | ||
| EP1257294A2 (en) | Carrier particles for drug delivery and process for preparation | |
| JP2021091730A (ja) | 多相組成物 | |
| UA111147C2 (uk) | Способи та композиції для лікування або профілактики зовнішнього отиту | |
| CN106456545A (zh) | 免疫原性的脂质体制剂 | |
| JP6374558B2 (ja) | 皮膚科障害または皮膚科疾患を処置するための新規製剤および方法 | |
| WO2012109151A1 (en) | Permeation enhancers with liposomes for topical formulations | |
| JP2017513938A (ja) | リポソームムピロシン | |
| JP2008528696A5 (enExample) | ||
| JP6991592B2 (ja) | 中枢神経系送達のためのコクリエート化抗真菌化合物及びクリプトコッカス感染症の治療 | |
| EP1909800B1 (de) | Acylglycerophospholipide zur behandlung von krebs-begleiterscheinungen | |
| HRP20230985T1 (hr) | Farmaceutske formulacije pegiliranih liposoma i faktora koagulacije krvi | |
| WO2026099472A1 (en) | Liposomal compositions for treatment of inflammation | |
| US8637688B2 (en) | Topical dosage form comprising tri-substituted glycerol compounds | |
| HK40070194A (en) | Compositions and methods for delivery of therapeutic agents |